Lexicon cuts about 75 sales jobs to prep for drug launch early next year
Ahead of an FDA decision date later this year, Lexicon Pharmaceuticals is trimming its workforce. The company will lay off roughly half of its sales
Ahead of an FDA decision date later this year, Lexicon Pharmaceuticals is trimming its workforce. The company will lay off roughly half of its sales
Brussels-based biopharma company UCB confirmed Thursday that it decided not to renew its membership in the industry group BIO in 2024, the second high-profile exit
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug